-
1
-
-
0002720261
-
Constituents of Cannabis sativa: A review of the natural constituents: 1980-1994
-
Ross S.A., Elsohly M.A. Constituents of Cannabis sativa: a review of the natural constituents: 1980-1994. J Pharm Sci. 4:1995;1-10.
-
(1995)
J Pharm Sci
, vol.4
, pp. 1-10
-
-
Ross, S.A.1
Elsohly, M.A.2
-
2
-
-
0038692066
-
Cannabis and the brain
-
Iverson L. Cannabis and the brain. Brain. 126:2003;1252-1270.
-
(2003)
Brain
, vol.126
, pp. 1252-1270
-
-
Iverson, L.1
-
3
-
-
85030903925
-
-
USA v Rosenthal. Case #CR02-0053CRB; June 9, 2003; Federal Supplement, #266F. Supp. 2d 1091
-
USA v Rosenthal. Case #CR02-0053CRB; June 9, 2003; Federal Supplement, #266F. Supp. 2d 1091.
-
-
-
-
4
-
-
0018778430
-
Marijuana may lessen spasticity of MS
-
Check W.A. Marijuana may lessen spasticity of MS. Am Medical Assoc J. 241:1979;2476.
-
(1979)
Am Medical Assoc J
, vol.241
, pp. 2476
-
-
Check, W.A.1
-
5
-
-
0023465839
-
Delta 9 THC in the treatment of spasticity associated with multiple sclerosis
-
Ungerleiter J.T., Andyrsiak T., Fairbanks L., et al. Delta 9 THC in the treatment of spasticity associated with multiple sclerosis. Adv Alc Sub Abuse. 7:1987;39-50.
-
(1987)
Adv Alc Sub Abuse
, vol.7
, pp. 39-50
-
-
Ungerleiter, J.T.1
Andyrsiak, T.2
Fairbanks, L.3
-
6
-
-
0024478281
-
Effect of cannabinoids on spasticity and ataxia in multiple sclerosis
-
Meinck H.M., Schonle P.W., Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 236:1989;120-122.
-
(1989)
J Neurol
, vol.236
, pp. 120-122
-
-
Meinck, H.M.1
Schonle, P.W.2
Conrad, B.3
-
7
-
-
0036628334
-
Cannabinoids in the treatment of pain and spasticity in multiple sclerosis
-
Smith P.F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs. 3:2002;859-864.
-
(2002)
Curr Opin Investig Drugs.
, vol.3
, pp. 859-864
-
-
Smith, P.F.1
-
8
-
-
0036669791
-
Cannabinoids and multiple sclerosis
-
Pertwee R.G. Cannabinoids and multiple sclerosis. Pharmacol Ther. 95:2002;165-174.
-
(2002)
Pharmacol Ther
, vol.95
, pp. 165-174
-
-
Pertwee, R.G.1
-
9
-
-
0043009728
-
Cannabis use as described by people with multiple sclerosis
-
Page S.A., Verhoef M.J., Strebbins R.A., et al. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci. 30:2003;181-182.
-
(2003)
Can J Neurol Sci
, vol.30
, pp. 181-182
-
-
Page, S.A.1
Verhoef, M.J.2
Strebbins, R.A.3
-
10
-
-
0037076468
-
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
-
Killestine J., Hoogervorst E.L.J., Reif M., et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 58:2002;1404-1407.
-
(2002)
Neurology
, vol.58
, pp. 1404-1407
-
-
Killestine, J.1
Hoogervorst, E.L.J.2
Reif, M.3
-
11
-
-
0242654882
-
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial
-
Zajicek J., Fox P., Sanders H., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 362:2003;1517-1526.
-
(2003)
Lancet
, vol.362
, pp. 1517-1526
-
-
Zajicek, J.1
Fox, P.2
Sanders, H.3
-
12
-
-
75949150955
-
Preliminary trial of carisoprodol in multiple sclerosis
-
Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 192:1964;540-542.
-
(1964)
Practitioner
, vol.192
, pp. 540-542
-
-
Ashworth, B.1
|